Preclinical humanized CD39 mouse model
The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.
![](https://cdn.prod.website-files.com/655b5a3d3d76e4eff6481da2/65b8bfab03e1c9348d5cf86f_cellule%201.png)
![](https://cdn.prod.website-files.com/655b5a3d3d76e4eff6481da2/65b8bfaacbee85e6e81e44c3_souris%201.png)
![](https://cdn.prod.website-files.com/655b5a3d3d76e4eff6481da2/65b8bfabf5f00b3aaec82ebf_rat%201.png)
Design of the hCD39 mouse
The humanized CD39 model, developed by Knockin at the mouse CD39 locus, expresses a chimeric CD39 with a human extracellular and murine transmembrane and intracellular domains. The design also gives access to CD39 conditional Knockout mice.
The human CD39 expression recapitulates murine CD39 expression. hCD39 is functional: α-human CD39 specifically reduces human CD39 activity.
hCD39 features
- The CD39 extracellular domain is entirely humanized
- Physiological regulation and expression pattern of the human CD39
- Fully functional mouse immune system
- Lack of expression of the murine target gene, thus avoiding cross-reactivity
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/65e86c5a38445bda8b96a888_65b115e49a560d60b2dfc2be_img02b.jpeg)
Validation
hCD39 expression pattern recapitulates mCD39
hCD39 and mCD39 expression on freshly isolated splenocytes on A) dendritic cells (CD3-CD19-CD11b+CD11c+), B) B cells (CD3-CD19+), and C) Tregs (viable, CD3+CD4+CD25+Foxp3+).
hCD39 is functional: anti-human CD39 specifically reduces human CD39 activity
Freshly isolated splenocytes from A) Wild-type and B) hCD39 mice, stimulated with anti-mCD39, anti-hCD39 or inhibitor control ARL (ectonucleotidases inhibitor) for 1h. ATP level was measured by CellTiter-Glo® luminescent cell assay following ATP addition. Results are expressed as mean±SD. Two-way ANOVA (**p<0.01; ***p<0.001; ****p<0.0001)
Discover related products to
hCD39
![](https://cdn.prod.website-files.com/655b5a3d3d76e4eff6481da2/65b8bfaacbee85e6e81e44c3_souris%201.png)
hGITR/Foxp3
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Preclinical humanized CD39 mouse model
Get in touch about
Let us know how we can help
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate